A detailed history of Halpern Financial, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Halpern Financial, Inc. holds 1,588 shares of AZN stock, worth $106,713. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,588
Previous 1,827 13.08%
Holding current value
$106,713
Previous $142 Million 11.31%
% of portfolio
0.03%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$76.67 - $87.62 $18,324 - $20,941
-239 Reduced 13.08%
1,588 $126 Million
Q1 2024

Apr 09, 2024

SELL
$61.03 - $69.57 $7,933 - $9,044
-130 Reduced 6.64%
1,827 $122 Million
Q4 2023

Jan 19, 2024

BUY
$61.89 - $69.28 $78,538 - $87,916
1,269 Added 184.45%
1,957 $134 Million
Q3 2023

Oct 10, 2023

SELL
$64.85 - $71.7 $7,652 - $8,460
-118 Reduced 14.64%
688 $46.6 Million
Q2 2023

Sep 21, 2023

BUY
$69.91 - $75.81 $1,258 - $1,364
18 Added 2.28%
806 $57.7 Million
Q1 2023

Sep 21, 2023

SELL
$63.15 - $71.6 $15,787 - $17,900
-250 Reduced 24.08%
788 $54.7 Million
Q3 2022

Sep 21, 2023

SELL
$53.02 - $135.75 $8,536 - $21,855
-161 Reduced 13.43%
1,038 $56.9 Million
Q2 2022

Sep 21, 2023

SELL
$59.26 - $71.14 $14,577 - $17,500
-246 Reduced 17.02%
1,199 $79.2 Million
Q3 2021

Sep 21, 2023

SELL
$55.56 - $60.79 $35,113 - $38,419
-632 Reduced 30.43%
1,445 $86.8 Million
Q2 2021

Sep 21, 2023

BUY
$48.42 - $60.18 $8,231 - $10,230
170 Added 8.91%
2,077 $124 Million
Q4 2020

Sep 21, 2023

SELL
$48.52 - $58.02 $9,704 - $11,604
-200 Reduced 9.49%
1,907 $95.3 Million
Q3 2020

Sep 21, 2023

SELL
$53.07 - $61.1 $12,312 - $14,175
-232 Reduced 9.92%
2,107 $115 Million
Q2 2020

Sep 21, 2023

BUY
$43.1 - $55.31 $100,810 - $129,370
2,339 New
2,339 $124 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $208B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Halpern Financial, Inc. Portfolio

Follow Halpern Financial, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Halpern Financial, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Halpern Financial, Inc. with notifications on news.